<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01067625</url>
  </required_header>
  <id_info>
    <org_study_id>TR-0009 Rev F</org_study_id>
    <nct_id>NCT01067625</nct_id>
  </id_info>
  <brief_title>Endoscopic Bariatric Stapling Pilot Study</brief_title>
  <acronym>TOGA®</acronym>
  <sponsors>
    <lead_sponsor>
      <agency>Satiety, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Satiety, Inc.</source>
  <brief_summary>
    <textblock>
      This study is a prospective single-arm, multicenter study to evaluate the safety and&#xD;
      effectiveness of the TOGA® Procedure for the treatment of morbid obesity.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Enrolling by invitation</last_known_status>
  <start_date>February 2006</start_date>
  <primary_completion_date type="Anticipated">December 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent excess weight loss (%EWL)</measure>
    <time_frame>up to 60 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Adverse events, including serious adverse events, will be recorded to determine safety</measure>
    <time_frame>up to 60 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Improvement in Co-morbidities</measure>
    <time_frame>up to 60 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvements in other Obesity Measures and Change in Quality Of Life Measures</measure>
    <time_frame>up to 60 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>TOGA subjects</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>TOGA® System</intervention_name>
    <description>Formation of restrictive sleeve via transoral gastric stapling for treatment of obesity</description>
    <arm_group_label>TOGA subjects</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age 18 years - 60 years&#xD;
&#xD;
          2. Eligible for bariatric surgery per US National Institute of Health (NIH) guidelines&#xD;
             BMI ≥ 40 kg/m2 and &lt; 55 kg/m2, or BMI ≥ 35 kg/m2 with one or more comorbidities.&#xD;
             Comorbidities are defined as diabetes, pulmonary disease, cardiac disease, or&#xD;
             hypertension [systolic blood pressure of ≥140 mm Hg or diastolic blood pressure ≥ 90&#xD;
             mm Hg (or both) or on treatment for hypertension]&#xD;
&#xD;
          3. History of obesity for at least 2.5 years&#xD;
&#xD;
          4. History of failure with non-surgical weight loss methods.&#xD;
&#xD;
          5. Agree to comply with the substantial dietary restrictions required by the procedure.&#xD;
&#xD;
          6. Understands risks of procedures, agree to follow protocol requirements, including&#xD;
             signing informed consent, returning for follow-up visits and completing all required&#xD;
             testing, completing diet and behavior modification counseling.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patient history of inflammatory disease of the gastrointestinal tract including&#xD;
             Crohn's disease or ulcerative colitis.&#xD;
&#xD;
          2. Significant known esophageal disease including grade 3-4 esophagitis, stricture,&#xD;
             Barrett's esophagus, esophageal cancer, esophageal diverticulum, nutcracker esophagus,&#xD;
             achalasia, esophageal dysmotility.&#xD;
&#xD;
          3. Severe coagulopathy, upper GI bleeding conditions such as esophageal or gastric&#xD;
             varices, congenital or acquired telangiectasia.&#xD;
&#xD;
          4. Congenital or acquired anomalies of the GI tract such as atresias or stenoses.&#xD;
&#xD;
          5. Hiatal hernia ≥2cm&#xD;
&#xD;
          6. Severe cardiopulmonary disease or other serious organic disease including HIV or&#xD;
             cancer.&#xD;
&#xD;
          7. Currently pregnant or nursing. Potentially childbearing (i.e not post-menopausal or&#xD;
             surgically sterilized) and not willing to use an effective method of contraception for&#xD;
             the next 12 months.&#xD;
&#xD;
          8. Current alcohol or drug addiction.&#xD;
&#xD;
          9. Mentally retarded or emotionally unstable, or exhibits psychological characteristics&#xD;
             which, in the opinion of the investigator or psychologist/psychiatrist, make the&#xD;
             subject a poor candidate for this procedure.&#xD;
&#xD;
         10. Previous gastric, esophageal, pancreatic, or bariatric surgery.&#xD;
&#xD;
         11. Infection anywhere in the body at the time of the procedure.&#xD;
&#xD;
         12. Patient history of scleroderma.&#xD;
&#xD;
         13. Thyroid disease which is not controlled with medication.&#xD;
&#xD;
         14. Participating in another ongoing clinical trial in which concomitant diagnosis or&#xD;
             therapeutic intervention would adversely affect the integrity of the clinical trial.&#xD;
&#xD;
         15. Known active H-pylori infection.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>ULB (Universite Libre de Bruxelles) - Erasme Hospital</name>
      <address>
        <city>Bruxelles</city>
        <zip>1070</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Università Cattolica del Sacro Cuore - Policlinico A. Gemelli</name>
      <address>
        <city>Rome</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Italy</country>
  </location_countries>
  <verification_date>February 2010</verification_date>
  <study_first_submitted>February 10, 2010</study_first_submitted>
  <study_first_submitted_qc>February 10, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 11, 2010</study_first_posted>
  <last_update_submitted>February 10, 2010</last_update_submitted>
  <last_update_submitted_qc>February 10, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 11, 2010</last_update_posted>
  <responsible_party>
    <name_title>Allan L. Abati, Ph.D., VP, RA/QA and Clinical Programs</name_title>
    <organization>Satiety, Inc.</organization>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

